2026

Tesini, G. et al. (2026) Longitudinal liquid biopsy and matched radiomic analysis of patients with biliary tract cancer undergoing systemic treatment. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-26-1550) (PMID:42820828) (Early Online Publication)

Iveson, T. et al. (2026) Three versus 6 months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy for colorectal cancer: final results of SCOT—an international, randomized, phase III, noninferiority trial. Journal of Clinical Oncology, 44(7), pp. 534-539. (doi: 10.1200/jco-25-00621) (PMID:41512219) (PMCID:PMC12931879)

2024

Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)

2023

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

2021

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

2019

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)

2018

Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)

1999

Wilson, K.E., Bartlett, J.M.S., Miller, E.P., Smyth, J.F., Mullen, P., Miller, W.R. and Langdon, S.P. (1999) Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. British Journal of Cancer, 80(5-6), pp. 685-692. (doi: 10.1038/sj.bjc.6690410)

Articles

Tesini, G. et al. (2026) Longitudinal liquid biopsy and matched radiomic analysis of patients with biliary tract cancer undergoing systemic treatment. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-26-1550) (PMID:42820828) (Early Online Publication)

Iveson, T. et al. (2026) Three versus 6 months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy for colorectal cancer: final results of SCOT—an international, randomized, phase III, noninferiority trial. Journal of Clinical Oncology, 44(7), pp. 534-539. (doi: 10.1200/jco-25-00621) (PMID:41512219) (PMCID:PMC12931879)

Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)

Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)

Wilson, K.E., Bartlett, J.M.S., Miller, E.P., Smyth, J.F., Mullen, P., Miller, W.R. and Langdon, S.P. (1999) Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. British Journal of Cancer, 80(5-6), pp. 685-692. (doi: 10.1038/sj.bjc.6690410)